期刊文献+

新型冠状病毒疫苗接种后发生急性荨麻疹19例临床分析 被引量:3

Clinical analysis of 19 cases with acute urticaria after vaccination of COVID-19 vaccine (vero cell)
下载PDF
导出
摘要 回顾分析2021年1月至2021年6月我院新型冠状病毒疫苗(北京生物生产)接种后发生的19例急性荨麻疹的临床资料。19例患者中,男8例,女11例,最小年龄18岁,最大年龄60岁。1例患者于疫苗注射后1小时,周身出现红色风团,喉头水肿,轻微憋喘症状,其余18例均于注射疫苗24小时内周身出现风团,瘙痒明显,无发热、关节痛等伴随症状,19例患者给予相应治疗后,均痊愈。 The clinical data of 19 cases with acute urticaria after vaccination of COVID-19 vaccine(vero cell),(Beijing Institute of Biological Products Co,Ltd) were retrospectively analyzed in our hospital from January 2021 to June 2021.Of 19 patients,8 were males and 11 were females,aged from 18 to 60 years old.One patient presented with wheals,laryngeal edema,with slight suffocation after 1 h of vaccination,and 18 patients presented with wheals and itching after 24 h of vaccination.All 19 patients were cured after treatment.
作者 万笑 魏志平 路全胜 WAN Xiao;WEI Zhiping;LU Quansheng(Department of Dermatology,The People' Hospital of Jiawang District of Xuzhou,Xuzhou 221000,Jiangsu,China;Department of Dermatology,Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China)
出处 《中国麻风皮肤病杂志》 2022年第3期170-171,共2页 China Journal of Leprosy and Skin Diseases
基金 徐州市卫生健康委青年医学科技创新项目(编号:XWKYHT20200011)。
关键词 新型冠状病毒疫苗 急性荨麻疹 临床分析 COVID-19 vaccine(vero cell),Inactivated acute urticaria clinical analysis
  • 相关文献

参考文献5

二级参考文献30

  • 1王侠生.杨国亮.皮肤病学[M].上海:上海科学技术文献出版社,2005.245-246.
  • 2顾伟程,刘彤.新编皮肤科用药手册[M].北京:中国协和医科大学出版社,2000.163.
  • 3Roumestan C, Henriquet C, Gougat C, et al. Histamine Hl-re-ceptor antagonists inhibit nuclear factor -kappaB and activatorprotein-1 activities via H1 -receptor-dependent and -independentmechanisms [J].Clin Exp Allergy, 2008,38(6): 947-956.
  • 4Kaplan AP. What the first 10,000 patients with chronic urticariahave taught me:a personal journey [J]. J Allergy Clin Immunol,2009, 123(3): 713-717.
  • 5Marzano AV, Tavecchio S, Venturini M, et al. Urticarial vasculi- tis and urticarial autoinflammatory syndromes[J]. G hal Derma- tol Venereol, 2015, 150(1): 41-50.
  • 6朱学骏,王宝玺,孙建方,等.皮肤病治疗学[M].北京:北京大学出版社,2011:339-343.
  • 7Egami N, Kakigi A, Takeda T, et al. Type 1 allergy-induced endolymphatic hydrops and the suppressive effect of HI-receptor antagonist (Olopatadine Hydroehloride)[J]. Otol Neurotol, 2014, 35(3) : e104-e109.
  • 8Varghese SJ, Kumar AM, Ravi TK. Stability-indicating high- performance column liquid chromatography and high-performance thin-layer chromatography methods for the determination of olopatadine hydroehloride in tablet dosage folxu[J]. J AOAC Int, 2011, 94(6): 1815-1820.
  • 9Bhatia NM, Ganbavale SK, Bhatia MS, et al. RP-HPLC and spectrophotometric estimation of ambroxol hydrochloride and cet- irizine hydrochloride in combined dosage form [J]. Indian J Pharm Sci, 2008, 70(5): 603-608.
  • 10Fukushima A, Ebihara N. Efficacy of olopatadine versus epinas- tine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial[J]. Adv Ther, 2014, 31(10): 1045-1058.

共引文献441

同被引文献20

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部